Global Organ Rejection Prophylaxis Drugs Market Revenue to Record Robust Growth in the Years After the End of COVID-19 Crisis and Forecast 2018 – 2026

The COVID-19 pandemic has caused supply and manufacturing disruptions in the Healthcare creating uncertainties in every aspect. The change in customer behavior in terms of mobility preferences during this crisis is changing the Healthcare landscape.

This pandemic situation has shut down many production lines owing to the trade restrictions and closed borders, creating a shortage in required parts and limiting the distribution of supplies. Different enforced measures including the closing of workspaces and dismissal of short-time workers have created a depression in the growth rate of the Healthcare Industry.

The growing fear of recession is estimated to decrease overall sales and revenue. A limited supply of parts coupled with a reduced workforce has forced the leading OEMs to shut down their production. A significant drop in demand has restricted the cash inflow which is highly important in payment of salaries to the workforce. With growing uncertainties around the COVID-19 pandemic, the industry leaders are taking measures to adapt to the situation.

Organ rejection prophylaxis drugs are intended to prevent graft rejection, reduce morbidity, and complications prior to or during transplant surgery. Universal organ rejection prophylaxis drugs involve administration of an antimicrobial agent to contain risk for infection while pre-emptive organ rejection prophylaxis drugs are aimed at neutralizing antigens and antibodies so as to avoid graft rejection by immunosuppression.

Organ Rejection Prophylaxis Drugs Market: Drivers and Restraints

The rising organ replacement surgeries are the prime driver of the organ rejection prophylaxis drugs market. According to the National Kidney Foundation, 107 kidney transplants took place in the U.S. in 2014. According to Organ Donation Foundation of South Africa (ODF), 512 solid organs and corneas were transplanted in South Africa, in 2016 and 4 300 patients were in waiting lines for organs.  The long waiting times owing to the high demand for organ transplant is expected to drive a sustainable market. According to estimates of the American Transplant Foundation, 115,000 patients in the U.S. are on the waiting list for an organ transplant.

The growing risk factors resulting in organ damage such as trauma, increase in geriatric patients and diseases such as diabetes, hypertension, and stroke is driving a large patient base for an organ transplant. The growing rates of organ donations owing to awareness is another driver of the market. According to the American Transplant Foundation, one-fourth donors are not biologically related to the recipient, resulting in greater risk of organ rejection.

However, the constraints such as high cost of organ transplant surgery, scarcity of organs, and the high cost of drugs coupled are hampering the organ rejection prophylaxis drugs market. Ethical issues such as possible negative externalities are also restricting the market. Concerns regarding social and economic inequality owing to wealthy individuals benefiting and disadvantaging poor people is another barrier that has to be mitigated. The poor healthcare infrastructure and the paucity of trained surgeons is another barrier to the market.

For detailed insights on enhancing your product footprint, request for a Sample Report here  https://www.persistencemarketresearch.com/samples/26959

Organ Rejection Prophylaxis Drugs Market: Segmentation

To gain a comprehensive and a better understanding of the future market equity, the organ rejection prophylaxis drugs report is segmented based on drug class, and application.

Based on drug class, the global organ rejection prophylaxis drugs market is segmented into:

  • Cytostatics
  • Corticosteroids
  • Antibodies
  • Immunophilins
  • Others

Based on applications, the global organ rejection prophylaxis drugs market is segmented into:

  • Chest
    • Heart
    • Lung
    • Heart
  • Abdomen
    • Kidney
    • Liver
    • Pancreas
  • Other Tissues, cells and fluids
    • Cornea
    • Skin
    • Bone, bone marrow/Adult stem cell
    • Others

To receive extensive list of important regions, ask for TOC here https://www.persistencemarketresearch.com/toc/26959

Organ Rejection Prophylaxis Drugs Market: Overview

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, Rest Of MEA)

North America led by the U.S. is expected to account for the largest share of the global organ rejection prophylaxis drugs market owing to excellent healthcare infrastructure, large per capita income, developed economy, attractive reimbursement and faster adoption of new technology.

The Europe organ rejection prophylaxis drugs markets are expected to be led by the Germany, France, Italy, Spain, Portugal and the UK. Germany has a large pharmaceutical industry which is a prime driver of the European organ rejection prophylaxis drugs market. The Latin America and the Middle East and Africa organ rejection prophylaxis drugs market is constrained due to the low healthcare expenditure and poor economic conditions. The Middle East and Africa organ rejection prophylaxis drugs market is projected to be dominated by the Gulf economies of UAE, Saudi Arabia, and Kuwait owing to their large wealth relative to the African nations.

The Asia Pacific market is expected to expand at a furious pace owing to growing research and development expenditure and the support of the governments to the technology sector. The growing economy of China and India is expected to drive large market adoption.

For in-depth competitive analysis, Check Pre-Book here  https://www.persistencemarketresearch.com/checkout/26959

Some of the major players in the global organ rejection prophylaxis drugs market are ,

  • Novartis AG
  • Astellas Pharma, Inc.
  • CSC Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Sanofi

The organ rejection prophylaxis drugs report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on organ rejection prophylaxis drugs market segments and geographies.

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.

Recommended For You

About the Author:

Leave a Reply

Your email address will not be published. Required fields are marked *